ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BMRN icon
126
BioMarin Pharmaceuticals
BMRN
$10.7B
$2.8M 0.13%
49,000
+30,800
+169% +$1.69M
2025 Q1
5 quarters
SMMT icon
127
Summit Therapeutics
SMMT
$12.1B
$2.8M 0.13%
191,869
+100,000
+109% +$1.77M
2025 Q2
4 quarters
KROS icon
128
Keros Therapeutics
KROS
$219M
$2.64M 0.12%
246,818
+149,500
+154% +$1.67M
2023 Q4
10 quarters
ELDN icon
129
Eledon Pharmaceuticals
ELDN
$183M
$2.55M 0.12%
647,812
-326,609
-34% -$1.19M
2025 Q4
2 quarters
SNY icon
130
Sanofi
SNY
$95.3B
$2.44M 0.11%
57,100
-259,839
-82% -$11.6M
2025 Q2
4 quarters
AEXA icon
131
American Exceptionalism Acquisition Corp
AEXA
$534M
$2.43M 0.11%
205,408
-152,131
-43% -$1.72M
2025 Q3
3 quarters
TNGX icon
132
Tango Therapeutics
TNGX
$3.74B
$2.4M 0.11%
76,761
+26,761
+54% +$662K
2025 Q4
2 quarters
ISRG icon
133
Intuitive Surgical
ISRG
$148B
$2.4M 0.11%
6,030
+4,200
+230% +$1.83M
2025 Q4
2 quarters
INO icon
134
Inovio Pharmaceuticals
INO
$102M
$2.36M 0.11%
2,143,910
+673,802
+46% +$800K
2025 Q4
2 quarters
OABI icon
135
OmniAb
OABI
$662M
$2.33M 0.11%
947,412
+242,222
+34% +$481K
2023 Q4
10 quarters
CAPR icon
136
Capricor Therapeutics
CAPR
$383M
$2.18M 0.1%
90,593
– –
2026 Q1
1 quarter
DRUG icon
137
Bright Minds Biosciences
DRUG
$500M
$2.13M 0.1%
30,300
-3,600
-11% -$283K
2025 Q4
2 quarters
ORKA icon
138
Oruka Therapeutics
ORKA
$5.08B
$1.98M 0.09%
20,840
– –
2025 Q1
5 quarters
YARW
139
Yarrow Bioscience
YARW
$159M
$1.92M 0.09%
59,000
+37,722
+177% +$1.22M
2025 Q4
2 quarters
MCK icon
140
McKesson
MCK
$114B
$1.89M 0.09%
2,500
+1,300
+108% +$1.03M
2025 Q4
2 quarters
LXRX icon
141
Lexicon Pharmaceuticals
LXRX
$712M
$1.8M 0.08%
750,000
– –
2026 Q1
1 quarter
CRVS icon
142
Corvus Pharmaceuticals
CRVS
$789M
$1.75M 0.08%
117,101
+29,200
+33% +$405K
2025 Q4
2 quarters
CUE icon
143
Cue Biopharma
CUE
$135M
$1.74M 0.08%
+55,193
New +$1.25M
2026 Q2
0 quarters
MSLE icon
144
Satellos Bioscience
MSLE
$141M
$1.73M 0.08%
222,555
– –
2026 Q1
1 quarter
KNSA icon
145
Kiniksa Pharmaceuticals
KNSA
$6.15B
$1.72M 0.08%
26,913
– –
2023 Q4
10 quarters
CNTB icon
146
Connect Biopharma Holdings
CNTB
$57.2M
$1.67M 0.08%
700,000
-42,400
-6% -$103K
2026 Q1
1 quarter
CCIIU icon
147
Cohen Circle Acquisition Corp II Unit
CCIIU
$272M
$1.58M 0.07%
150,000
– –
2025 Q3
3 quarters
RCKT icon
148
Rocket Pharmaceuticals
RCKT
$243M
$1.49M 0.07%
435,500
+3,000
+0.7% +$9.98K
2024 Q2
8 quarters
TRAX icon
149
First Tracks Biotherapeutics
TRAX
$1.22B
$1.45M 0.07%
+71,910
New +$1.34M
2026 Q2
0 quarters
EVMN icon
150
Evommune Inc
EVMN
$209M
$1.38M 0.06%
104,035
-80,027
-43% -$1.86M
2025 Q4
2 quarters
4 5
6
7 8

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.